IMMUNOVANT INC
IMVTNASDAQTrading Snapshot
- Day Range
- $40.32 – $41.16
- 52-Week Range
- $14.47 – $41.23
- Volume
- $6.10B
- Avg Volume
- $6.92B
- Shares Outstanding
- 206.4M
- Next Earnings
- Oct 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $7M
- P/E Ratio
- -14.5
- P/S Ratio
- 1190.7x
- EPS (TTM)
- $-2.62
- Dividend Yield
- 0.00%
Why Investors Own IMVT
- ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About IMMUNOVANT INC
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsConference Call ParticipantsStephanie Lee Griffin - Roivant...
Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71) per share from the
JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $47 to $50.
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy
Initiate coverage of Immunovant (IMVT) with a BUY and $50 price target based on IMVT-1402âs best-in-class IgG reduction and ~$4B peak sales outlook. See more.
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant. To access the Roivant (Nasdaq: ROIV) conference call by phone, please reg
Tracking Baker Brothers Portfolio: Q1 2026 Update
Baker Brothersâ Q1 2026 13F: $17.42B biotech portfolio, top holdings & key buys/sells. Click here to read more.